Floatz Rating
B60/100
Confidence
Indicative
Sponsor
LaNova Medicines Limited
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07561983CT.gov Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07390383CT.gov A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] | — | Recruiting | — | — | — |
NCT07414836CT.gov A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07331155CT.gov A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] | — | Recruiting | — | — | — |
NCT07396090CT.gov Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT06332274CT.gov tislelizUMaB in canceR Patients With molEcuLar residuaL Disease | — | Recruiting | — | — | — |
NCT06825494CT.gov Clinical Studies for the Treatment of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06596473CT.gov A Study of BG-C477 in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06540066CT.gov A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT06422520CT.gov A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
Show 23 more trialsShow fewer
NCT06431243CT.gov A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06233942CT.gov Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07085182CT.gov Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study | — | Recruiting | — | — | — |
NCT05981703CT.gov A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05978102CT.gov A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05935098CT.gov BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors | — | Terminated | — | — | — |
NCT05904496CT.gov A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT05840835CT.gov Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
NCT05768932CT.gov BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT05547321CT.gov Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors. | — | Recruiting | — | — | — |
NCT05505877CT.gov Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors | — | Unknown | — | — | — |
NCT05508100CT.gov Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors | — | Completed | — | — | — |
NCT05014828CT.gov To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors | — | Completed | — | — | — |
NCT04789434CT.gov PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT | — | Unknown | — | — | — |
NCT07198217CT.gov Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient | — | Recruiting | — | — | — |
NCT04716634CT.gov Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors | — | Completed | — | — | — |
NCT04799314CT.gov PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT | — | Unknown | — | — | — |
NCT04649385CT.gov BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05244837CT.gov Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC | — | Unknown | — | — | — |
NCT04282018CT.gov Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | — | Completed | — | — | — |
NCT04215978CT.gov Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03666143CT.gov A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04068519CT.gov Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tislelizumab (this asset) | LaNova Medicines Limited | P3 | B · 60 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Tislelizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 69 |
| Diffuse Large B-Cell Lymphoma | — | P3 | BB · 67 |
| Classic Hodgkin Lymphoma | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tislelizumab in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tislelizumab-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →